- Liposomal Product Characterization
- Liposome Encapsulation
- Formulation Solutions
- Custom Liposomes
- Process Development and Scale-up
Get QuoteOnline Inquiry
Liposome Encapsulation Services: siRNA, miRNA, DNA, ProteinsOnline Inquiry
BOC Sciences provides efficient liposome encapsulation services for your siRNA, miRNA, DNA, and proteins, ensuring the safety of in vivo delivery.
In vivo siRNA-induced therapeutic gene silencing (RNAi) is achieved by efficiently delivering small RNA molecules, including siRNA, small hairpin RNA (shRNA), and microRNA (miRNA), into tissues. The use of liposomes for in vivo delivery can protect RNAs/DNA/proteins from degradation and achieve accurate delivery into cells or tissues for research or therapeutic purposes.
An ideal RNAs vector should have the following three key characteristics for effective systemic delivery
- Extend blood circulation time for effective accumulation
- Effective penetration into lesion tissue (such as tumors)
- High cellular uptake and effective endosome escape
Gene carriers should be able to reach target tissues through vascular endothelium and extracellular matrix.
The gene vector should have high enough cellular uptake and effective endosome escape to allow RNAs release from the endosome, resulting in high cytoplasmic transmission.
Liposomes are the most widely studied vectors for in vivo delivery of various types of nucleic acids or proteins due to their excellent biodegradability and biocompatibility.
What We Provide?
BOC Sciences liposome platform uses the latest microfluidics technology and achieves liposome protection of functional siRNA, shRNA, miRNA, mRNA, plasmid DNA, and protein molecules, providing uniform target particle size and enhancing in vivo delivery efficiency. We design the optimal size for each liposome to ensure the correct release of active ingredients into cells in the body. We use different liposomes to accommodate different delivery routes (topical, oral, pulmonary or parenteral).
Customers should provide a liposome-encapsulated dose of at least 0.25 mg. We deliver encapsulated liposome products to customers in sterile vials to ensure consistency and eliminate potential contamination.
Figure 1: A scheme systemic delivery of liposomal siRNA formula (Yuqiong Xia. 2016).
Contact us for a free consultation to design and customize liposome encapsulation services for different active ingredients.
- Yuqiong Xia, Jie Tian, and Xiaoyuan Chen. Effect of Surface Properties on Liposomal siRNA Delivery. Biomaterials. 2016 Feb; 79: 56–68.